Donaldson to acquire 49% stake in Medica, terms undisclosed

Donaldson announced it has entered into a definitive agreement allowing the company to purchase a 49% stake in Medica. Medica is a leader in hollow fiber membrane filtration technology for medical device applications and water purification. Headquartered in Medolla, Italy, the company has over 700 employees globally and generated EUR 80M of revenue in calendar 2023. Founded in 1985, Medica’s hollow fiber membrane filtration products are used for blood purification in numerous applications including dialysis, continuous renal replacement therapies, or CRRT, and therapeutic apheresis. The company’s products and technologies are also used in the microbiological purification of water, as well as automation solutions for disposable medical device manufacturing. The acquisition is subject, inter alia, to the outcome of the voluntary totalitarian tender offer on the ordinary shares of Medica, which MavenDanc, an Italian company entirely owned by Donaldson, formally announced to the market on the date hereof by way of publication of the communication required by article 102, paragraph 1, of Legislative Decree n. 58 of 24 February 1998. Copy of the 102 Notice is available to the public on Medica website at www.medica-spa.com. Upon positive outcome of the tender offer, Donaldson will acquire a 49% stake of Medica with the option to acquire the remaining 51% stake in the future. Completion of the transaction is expected by the third quarter of calendar 2024. Upon closing, the ratable share of Medica’s earnings would be included as a part of the Donaldson Life Sciences segment.